Design Therapeutics, Inc.
DSGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $14,589 | $152 | $0 | $0 |
| Gross Profit | -$14,589 | -$152 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,589 | $15,738 | $15,377 | $12,157 |
| G&A Expenses | $4,652 | $5,831 | $5,041 | $4,537 |
| SG&A Expenses | $4,722 | $5,831 | $5,041 | $4,537 |
| Sales & Mktg Exp. | $70 | $0 | $0 | $0 |
| Other Operating Expenses | -$14,589 | -$152 | $0 | $0 |
| Operating Expenses | $4,722 | $21,417 | $20,418 | $16,694 |
| Operating Income | -$19,311 | -$21,569 | -$20,418 | -$16,694 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,314 | $2,486 | $2,703 | $3,043 |
| Pre-Tax Income | -$16,997 | -$19,083 | -$17,715 | -$13,651 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16,997 | -$19,083 | -$17,715 | -$13,651 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.34 | -0.31 | -0.24 |
| % Growth | 11.8% | -9.7% | -29.2% | – |
| EPS Diluted | -0.3 | -0.34 | -0.31 | -0.24 |
| Weighted Avg Shares Out | 56,951 | 56,859 | 56,758 | 56,682 |
| Weighted Avg Shares Out Dil | 56,951 | 56,859 | 56,758 | 56,682 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,314 | $2,486 | $2,703 | $3,043 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $155 | $152 | $159 | $149 |
| EBITDA | -$16,842 | -$18,931 | -$20,259 | -$16,545 |
| % Margin | – | – | – | – |